HC Wainwright Reaffirms “Buy” Rating for Arvinas (NASDAQ:ARVN)

Arvinas (NASDAQ:ARVN)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $81.00 price target on the stock.

Several other research firms have also recently weighed in on ARVN. Stephens assumed coverage on Arvinas in a report on Monday, November 18th. They set an “overweight” rating and a $55.00 price target on the stock. Citigroup decreased their target price on Arvinas from $28.00 to $19.00 and set a “neutral” rating on the stock in a report on Friday, March 7th. Wedbush reaffirmed an “outperform” rating and issued a $57.00 target price on shares of Arvinas in a report on Tuesday, February 11th. Stifel Nicolaus decreased their target price on Arvinas from $63.00 to $51.00 and set a “buy” rating on the stock in a report on Wednesday, February 12th. Finally, Barclays decreased their target price on Arvinas from $48.00 to $32.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.08.

Arvinas Price Performance

NASDAQ ARVN opened at $9.03 on Tuesday. The business’s fifty day moving average price is $17.97 and its 200-day moving average price is $22.20. The stock has a market capitalization of $621.01 million, a price-to-earnings ratio of -3.26 and a beta of 1.95. Arvinas has a 1-year low of $7.91 and a 1-year high of $46.51.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same quarter in the previous year, the business posted ($2.53) EPS. Equities research analysts anticipate that Arvinas will post -3.81 EPS for the current year.

Insider Buying and Selling at Arvinas

In other news, CEO John G. Houston sold 31,338 shares of the firm’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.72, for a total transaction of $523,971.36. Following the completion of the transaction, the chief executive officer now owns 1,157,480 shares in the company, valued at $19,353,065.60. This trade represents a 2.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Ian Taylor sold 9,020 shares of the firm’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the transaction, the insider now owns 159,121 shares of the company’s stock, valued at approximately $2,658,911.91. The trade was a 5.36 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 41,572 shares of company stock valued at $695,030 over the last ninety days. 5.23% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ARVN. Invesco Ltd. grew its position in Arvinas by 1.6% in the fourth quarter. Invesco Ltd. now owns 37,254 shares of the company’s stock worth $714,000 after acquiring an additional 581 shares in the last quarter. Rhumbline Advisers grew its position in Arvinas by 0.9% in the fourth quarter. Rhumbline Advisers now owns 87,877 shares of the company’s stock worth $1,685,000 after acquiring an additional 754 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Arvinas by 0.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 140,518 shares of the company’s stock worth $2,694,000 after acquiring an additional 777 shares in the last quarter. Bank of Montreal Can grew its position in Arvinas by 2.7% in the fourth quarter. Bank of Montreal Can now owns 39,407 shares of the company’s stock worth $755,000 after acquiring an additional 1,044 shares in the last quarter. Finally, KBC Group NV grew its position in Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after acquiring an additional 1,255 shares in the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.